01:11 PM EST, 02/20/2026 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) presented real world data showing early signals of hearing preservation in adults treated with platinum-based chemotherapy for head and neck cancer, notes Wedbush.

In a note, analyst David Nierengarten, who has an outperform rating and US$13.00 price target on the stock, said the majority of high-risk patients, including those with baseline hearing impairment, experienced no measurable hearing loss during or following treatment. Pedmark was generally well tolerated.

"While the dataset remains small, we view these findings as an encouraging early step toward addressing additional tumor types and patient populations."

Price: 12.02, Change: +0.27, Percent Change: +2.30